Part 1 Basic Information

Name:Liu Hongfei

Address:School of Pharmacy, Jiangsu University, Jingkou District, Zhenjiang City, Jiangsu Province, China

Email: Liuhongfei2000@163.com

Part 2 Personal Profile

Dr. Liu Hongfei is male, Associate Professor, Master's Supervisor and Senior Engineer at the School of Pharmacy, Jiangsu University. He is a recipient of the Jiangsu Provincial Science and Technology Vice-President Program and the Zhenjiang 169 Academic Leader Program. His long-term research focuses on novel drug delivery systems and the industrial development of biomedicine. He has presided over 3 provincial-ministerial research projects and 2 municipal-department-level projects, and participated in the completion of 3 National Natural Science Foundation of China projects (one of which he led within Jiangsu University). He has published more than 40 SCI papers as the first or corresponding author and serves as a young editorial board member of an SCI journal. He has obtained 7 authorized invention patents and 1 international PCT patent. As principal investigator, he has won 2 provincial-ministerial-level awards and 2 municipal-department-level awards, and as a participant he has completed 3 provincial-ministerial-level awards. He has presided over the completion of more than 20 biomedical transformation projects, with nearly 10 marketed drugs and more than 10 medical device products, generating economic benefits of more than 2 billion RMB for cooperating enterprises. The in-place research funding has reached nearly 10 million RMB, and he has supervised more than 30 graduated postgraduate students. He serves as a member of the Pharmaceutical Excipients Professional Committee of the Chinese Pharmaceutical Association and Deputy Director of the Jiangsu Engineering Research Center for Anti-Osteoarthritis Drugs, among other academic positions.

Part 3 Education

•2001.09—2005.06, Shenyang Pharmaceutical University, Pharmaceutics, Ph.D. (Combined Master‑PhD Program)

•1997.09—2001.07, Shenyang Pharmaceutical University, Pharmacy, Bachelor of Science

Part 4 Work Experience

•2011.01—Present, School of Pharmacy, Jiangsu University, Associate Professor, Master’s Supervisor

•2009.06—2010.06, Imperial College London, Postdoctoral Research Fellow

•2005.11—2008.11, Shenyang Pharmaceutical University / Northeast Pharmaceutical Group, Joint‑training Postdoctoral Research Fellow

Part 5 Research Interests

1.Industrial development of drugs — generic drug consistency evaluation and development of improved new drugs

2.Oral liquid sustained- and controlled-release drug delivery systems for pediatric drugs and development of key pharmaceutical excipients

3.Industrial development of targeted delivery of small nucleic acids

4.Industrial development of in vitro diagnostic and medical aesthetic medical devices

Part 6 Research Achievements

6.1 Research Projects

6.1.1 Industrialization Projects (Only representative projects with funding over 500,000 RMB are listed)

•2026.07—2029.07 | Pharmaceutical Excipients and Chemical Products Based on Anion Exchange Resin (Cholestyramine) | National Center for Technology Transfer and Transformation of Biomedicine in Higher Education Institutions (Jiangsu Nanjing), Ministry of Education (industrial investment: 2,000,000 RMB) | Principal Investigator

•2021.08—2031.08 | Research and Development of Implantable CMC Gel Loaded with PCL, PLLA and PLGA Biodegradable Microspheres | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. (funding: 500,000 RMB) | Principal Investigator

•2017.09—2027.09 | Research and Development of Carbinoxamine, Dexibuprofen and Dextromethorphan Sustained‑release Suspension | Jiangsu Sihuan Bio‑Pharmaceutical Co., Ltd. (funding: 550,000 RMB) | Principal Investigator

•2019.01—2020.12 | Generic Research and Development of Apixaban Tablets 2.5 mg | Zhejiang Tianyu Pharmaceutical Co., Ltd. (funding: 500,000 RMB) | Principal Investigator

•2019.10—2028.10 | Research and Development of Paroxetine Suspension, Ibuprofen Sustained‑release Suspension, Metronidazole Sustained‑release Suspension and Esomeprazole Enteric‑coated Suspension | Shanghai Meiyou Pharmaceutical Co., Ltd. (funding: 1,150,000 RMB) | Principal Investigator

•2015.01-2017.01 | 2016 Jiangsu "Double Innovation Plan" Science and Technology Vice-President Program Funding | Talent Program of Jiangsu Provincial Department of Science and Technology | Principal Investigator

6.1.2 Vertical Projects

•2013.01—2015.01 | Establishment of Biodegradable Sustained‑release Microsphere System for Protein Growth Factors and Investigation of Protein Stabilization Mechanism | Scientific Research Foundation for Returned Overseas Chinese Scholars of Ministry of Education | Principal Investigator

•2012.10—2016.10 | Construction and Evaluation of Inorganic‑Organic Composite Sustained‑release Drug Delivery System with Retained Protein Activity Based on Electrospinning Technology | China Postdoctoral Science Foundation | Principal Investigator

•2011.07—2014.07 | Establishment of Sustained‑release Microsphere System Based on Electrospinning and Bioglass | Jiangsu Provincial Natural Science Foundation | Principal Investigator

•2026.01—2029.12 | Mechanism of Human Cytomegalovirus RNA2.7 Antagonizing Monocyte Death Induced by Viral Infection and Strategy for Targeted RNA2.7 to Specifically Kill Latently Infected and Reactivated Infected Cells | National Natural Science Foundation of China (General Program) | Principal Investigator (within Jiangsu University)

•2014.07—2017.07 | Technical Innovation Platform for Oral Liquid Sustained- and Controlled-release Drug Delivery Systems for Pediatric Drugs — Dextromethorphan Hydrobromide Sustained-release Suspension | Department of Science and Technology of Guangdong Province (Jointly declared with Guangzhou Pharmaceutical Holdings Limited) | Principal Investigator (within Jiangsu University)

•2018.01—2020.12 | Preparation of Bifunctional MONOLITH Materials by Phase Separation Method and Construction of Universal Platform for Efficient Separation, Purification and Site‑specific Modification of Protein Drugs | National Natural Science Foundation of China (Youth Program) | Participant (2/10)

•2017.01—2019.12 | Construction of Multi‑therapy Synergistic Nano‑delivery System and Its Application in Reversing Tumor Multidrug Resistance | National Natural Science Foundation of China (Youth Program) | Participant (2/8)

•2013.01—2015.12 | Design and Preparation of Trigger‑type Self‑assembled Protein‑polymer Nanocarriers Loaded with Bufalin and Its Liver Tumor Targeting Research | National Natural Science Foundation of China (Youth Program) | Participant (5/11)

6.2 Publications

1.Amino-functionalized poloxamer-hyaluronate in situ gels for sustained delivery of timolol maleate in glaucoma therapy. International Journal of Pharmaceutics, 2026, 689: 126499. Corresponding Author (SCI—CAS Q2, IF=5.3)

2.Enhanced ophthalmic bioavailability and stability of atropine sulfate via sustained release particles using polystyrene sulfonate resin[J]. International Journal of Pharmaceutics, 2024, 660: 124294. Corresponding Author (SCI—CAS Q2, IF=5.3)

3.Preparation and evaluation of sustained release pirfenidone-loaded microsphere dry powder inhalation for treatment of idiopathic pulmonary fibrosis[J]. European Journal of Pharmaceutical Sciences, 2023, 188: 106509. Corresponding Author (SCI—CAS Q2, IF=5.1)

4.Hypoxia responsive and tumor-targeted mixed micelles for enhanced cancer therapy and real-time imaging[J]. Colloids and Surfaces B: Biointerfaces, 2022, 215(6): 112526. Corresponding Author (SCI—CAS Q2, IF=5.8)

5.A Theranostic Nanocomplex Combining with Magnetic Hyperthermia for Enhanced Accumulation and Efficacy of pH-Triggering Polymeric Cisplatin(IV) Prodrugs[J]. Pharmaceuticals, 2022, 15: 480. Corresponding Author (SCI—CAS Q2, IF=5.2)

6.Dual-modified Albumin-polymer Nanocomplexes with Enhanced in Vivo Stability for Hepatocellular Carcinoma Therapy[J]. Colloids and Surfaces B: Biointerfaces, 2021, 201: 111642. Corresponding Author (SCI—CAS Q2, IF=5.9)

7.Improving the oral absorption of nintedanib by a self-microemulsion drug delivery system: preparation and in vitro/in vivo evaluation[J]. International Journal of Nanomedicine, 2019: 8739–8751. Corresponding Author (SCI—CAS Q2, IF=5.1)

6.3 Monographs and Textbooks

1.Liu Hongfei.(Associate Editor). New Formulations and New Technologies of Traditional Chinese Medicine[M]. Shenyang: Shenyang Press, 2012.03. (Published)

2.Liu Hongfei.(Contributor). Pharmaceutical Excipients and Pharmaceutical Packages, the 12th Five‑Year Planned Textbook of Ministry of Health[M]. Beijing: People’s Medical Publishing House, 2014.

6.4 Patents and Software Copyrights

1.Levosalbutamol Sulfate Pulsed Release Capsule and Preparation Method Thereof : CN102429892A[P] .2013.05.

2.A Ticagrelor Core-Shell Structured Solid Dispersion, Preparation Method Thereof and Ticagrelor Preparation :CN109718218A[P] .2020.12.

3. Porous Sodium Polystyrene Sulfonate Cation Exchange Resin, Preparation Method Thereof and Application :CN114471747A[P] .2024.05.

4.Preparation of Metformin Hydrochloride (Berberine Hydrochloride) Sustained-Release Suspension: WO2018214402. 2019.09. International PCT Patent.

5.Ranitidine Hydrochloride Controlled-release Dry Suspension and Preparation Method Thereof: CN105496967A[P] .2015.12

6. Preparation Method of Famotidine Drug Resin Microcapsules: CN106176672A[P] .2016.08

7.Acyclovir Drug Resin Bioadhesive Sustained-release Liquid Preparation and Preparation Method Thereof: CN1618427A[P] .2003.11

8.Venlafaxine Hydrochloride Liquid Sustained-release Preparation and Preparation Method Thereof: CN1634006[P] .2004.11

9.Method for Preparing Pharmaceutical Grade Excipient — Sodium Polystyrene Sulfonate Cation Exchange Resin by Sulfonation of Polystyrene-Divinylbenzene Microspheres: CN116284518A[P] .2021.12